Shengpeng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shengpeng Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Gang Zuo
Loma Linda University School of Medicine
2 shared publicationsJerry J. Flores
Loma Linda University School of Medicine
2 shared publicationsJun Peng
Shenzhen People's Hospital
2 shared publicationsShuixiang Deng
Huashan Hospital Fudan University
2 shared publicationsBo Li
Department of Pediatrics, Shenzhen People’s Hospital, the Second Clinical Medical College of Jinan University, Shenzhen, Guangdong, China
1 shared publicationJiping Tang
Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, California, USA
1 shared publication
Latest Publications
- Open Access
- 27 March 2023
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 3 (4) , 313-319
Oxidative stress as a bridge between age and stroke: A narrative review
- 27 March 2023
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 3 (4) , 313-319
Open AccessOxidative stress as a bridge between age and stroke: A narrative review
- Open Access
- 11 October 2021
- Published by Springer Nature in Research Square
Secukinumab Attenuates Neuroinflammation and Neurobehavior Defect via PKCβ /ERK/NF-κB Pathway in a Rat Model of GMH
AimsGerminal matrix hemorrhage (GMH) is a disastrous clinical event for newborns. Neuroinflammation plays an important role in the development of neurological deficits after GMH. The purpose of this study is to investigate the anti-inflammatory role of secukinumab after GMH and its underlying mechanisms involving PKCβ/ERK/NF-κB signaling pathway.MethodsA total of 154 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. Secukinumab was administered intranasally post-GMH. PKCβ activator PMA and p-ERK activator Ceramide C6 were administered intracerebroventricularly at 24h prior to GMH induction, respectively. Neurobehavioral tests, Western blot and immunohistochemistry were used to evaluate the efficacy of secukinumab in both short-term and long-term studies.ResultsEndogenous IL-17A, IL-17RA, PKCβ and p-ERK were increased after GMH. Secukinumab treatment improved short- and long-term neurological outcomes, reduced the expression of MPO and Iba-1 in the perihematoma area, and inhibited the expression of proinflammatory factors, such as NF-κB, IL-1β, TNF-α and IL-6. Additionally, PMA and ceramide C6 abolished the beneficial effects of secukinumab. ConclusionSecukinumab treatment suppressed neuroinflammation and attenuated neurological deficits after GMH, which was mediated through the downregulation of the PKCβ/ERK/NF-κB pathway. Secukinumab treatment may provide a promising therapeutic strategy for GMH patients.
- 11 October 2021
- Published by Springer Nature in Research Square
Open AccessSecukinumab Attenuates Neuroinflammation and Neurobehavior Defect via PKCβ /ERK/NF-κB Pathway in a Rat Model of GMH
AimsGerminal matrix hemorrhage (GMH) is a disastrous clinical event for newborns. Neuroinflammation plays an important role in the development of neurological deficits after GMH. The purpose of this study is to investigate the anti-inflammatory role of secukinumab after GMH and its underlying mechanisms involving PKCβ/ERK/NF-κB signaling pathway.MethodsA total of 154 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. Secukinumab was administered intranasally post-GMH. PKCβ activator PMA and p-ERK activator Ceramide C6 were administered intracerebroventricularly at 24h prior to GMH induction, respectively. Neurobehavioral tests, Western blot and immunohistochemistry were used to evaluate the efficacy of secukinumab in both short-term and long-term studies.ResultsEndogenous IL-17A, IL-17RA, PKCβ and p-ERK were increased after GMH. Secukinumab treatment improved short- and long-term neurological outcomes, reduced the expression of MPO and Iba-1 in the perihematoma area, and inhibited the expression of proinflammatory factors, such as NF-κB, IL-1β, TNF-α and IL-6. Additionally, PMA and ceramide C6 abolished the beneficial effects of secukinumab. ConclusionSecukinumab treatment suppressed neuroinflammation and attenuated neurological deficits after GMH, which was mediated through the downregulation of the PKCβ/ERK/NF-κB pathway. Secukinumab treatment may provide a promising therapeutic strategy for GMH patients.
- Open Access
- 19 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
IL‐20R Activation via rIL‐19 Enhances Hematoma Resolution through the IL‐20R1/ERK/Nrf2 Pathway in an Experimental GMH Rat Pup Model
Aims. Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin‐19’s role in hematoma clearance after GMH and its underlying mechanism of IL‐20R1/ERK/Nrf2 signaling pathway. Methods. A total of 240 Sprague‐Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL‐19 was administered intranasally 1 hour post‐GMH. IL‐20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short‐ and long‐term. Results. Endogenous IL‐19, IL‐20R1, IL‐20R2, and scavenger receptor CD163 were increased after GMH. rIL‐19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL‐20R1 CRISPR‐knockdown plasmid and ML385 inhibited the effects of rIL‐19 on CD163 expression. Conclusion. rIL‐19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL‐20R1/ERK/Nrf2 pathways. rIL‐19 treatment may provide a promising therapeutic strategy for the GMH patient population.
- 19 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessIL‐20R Activation via rIL‐19 Enhances Hematoma Resolution through the IL‐20R1/ERK/Nrf2 Pathway in an Experimental GMH Rat Pup Model
Aims. Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin‐19’s role in hematoma clearance after GMH and its underlying mechanism of IL‐20R1/ERK/Nrf2 signaling pathway. Methods. A total of 240 Sprague‐Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL‐19 was administered intranasally 1 hour post‐GMH. IL‐20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short‐ and long‐term. Results. Endogenous IL‐19, IL‐20R1, IL‐20R2, and scavenger receptor CD163 were increased after GMH. rIL‐19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL‐20R1 CRISPR‐knockdown plasmid and ML385 inhibited the effects of rIL‐19 on CD163 expression. Conclusion. rIL‐19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL‐20R1/ERK/Nrf2 pathways. rIL‐19 treatment may provide a promising therapeutic strategy for the GMH patient population.
- 1 October 2007
- Published by Springer Nature in Journal of Shanghai University (English Edition)
- Vol. 11 (5) , 464-468
A contourlet-transform based sparse ICA algorithm for blind image separation
- 1 October 2007
- Published by Springer Nature in Journal of Shanghai University (English Edition)
- Vol. 11 (5) , 464-468
A contourlet-transform based sparse ICA algorithm for blind image separation